In a recent article, Mercer Island Reporter journalist Andy Nystrom looks at the history and ongoing impact of the Ovarian Cancer Research Alliance (OCRA) Rivkin Family SummeRun, the iconic annual 5K Run/Walk event that continues to play a vital role in raising funds for ovarian cancer research. Join the 2025 SummeRun in Seattle This year’s … Continued
SEATTLE, WA — July 7, 2025 — Hundreds of runners, walkers, families, and even some four-legged friends will gather at Seward Park on Sunday, July 13, 2025, for the OCRA Rivkin Family SummeRun, raising critical funds for ovarian cancer research. Now entering its fourth decade, this iconic and impactful 5K run/walk has raised over $10 … Continued
OCRA Featured in Fortune Article on Surgery That Reduces Ovarian Cancer Risk Ovarian Cancer Research Alliance’s (OCRA) leadership in raising awareness about opportunistic salpingectomy—a simple procedure that can significantly reduce the risk of ovarian cancer—is at the center of a new Fortune article. The story features a personal perspective from journalist and breast cancer survivor … Continued
Written by Chad Ramsey, Vice President, Policy, Ovarian Cancer Research Alliance FY26 Budget Update: Critical Cancer Programs at Risk Congress is deep into its work on the fiscal year 2026 (FY26) appropriations bills, and decisions made now will shape the future of cancer care, prevention, and research. While there is strong bipartisan support for cancer … Continued
A Fortune article published on June 16, 2025, titled I had one simple surgery to lower my risk of the deadliest cancer for women. Here’s why you probably don’t know about it—but should, highlights an effective but underused way to reduce the risk of ovarian cancer: opportunistic salpingectomy, the removal of the fallopian tubes during another … Continued
New collaboration enhances support for gynecologic cancer patients through integrated digital and personalized care New York, NY — [June 11, 2025] — Ovarian Cancer Research Alliance (OCRA), the largest global organization dedicated to advancing ovarian and all gynecologic cancer research and supporting patients and their families, is proud to announce a strategic partnership with Iris by … Continued
Global Collaborative Research Push Resonates Across Airwaves The launch of the Global Ovarian Cancer Research Consortium has garnered significant media attention, with coverage appearing on NBC News Radio, FOX 5 Washington D.C., KUNS-TV Seattle, WRC-TV Washington D.C. (NBC), WJFF-FM New York (NPR affiliate), and FemTech Insider, among others. The Consortium’s inaugural initiative is a new AI Accelerator Grant — a … Continued
FY26 Budget Watch, Advocacy Results, and State-Level Progress As Congress ramps up work on the FY26 federal budget, advocates are focused on maintaining vital cancer programs and advancing state policies that support gynecologic cancer patients. Here’s what’s happened over the last month—and what’s next. Budget Update: CDC Cancer Programs at Risk The administration’s proposed FY26 … Continued
Uterine (or endometrial) cancer is the most common type of gynecologic cancer, with more than 886,000 women living with the disease in the U.S., according to National Cancer Institute’s SEER Cancer Statistics. As Ovarian Cancer Research Alliance funds research that aims to cure ovarian and related gynecologic cancers, we are here for those impacted by … Continued
In a wide-ranging interview on the podcast Out of Patients with Matthew Zachary, OCRA’s President & CEO Audra Moran delves into the evolution of the organization, the unique programs offered by OCRA such as our peer mentorship program Woman to Woman, and thoughts on how AI may revolutionize ovarian cancer research. Listen to the podcast … Continued
The Food and Drug Administration has granted accelerated approval to Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets), made by Verastem Oncology, making it the first FDA-approved treatment for patients with recurrent low-grade serous ovarian cancer (LGSOC) who have a KRAS mutation. The approval is based on the results of the Phase 2 RAMP 201 clinical … Continued
Liliana is a mother, a wife, a dedicated volunteer and a former physician. While her cancer diagnosis forced her into early retirement, her mission to help others never wavered. Today, OCRA programs made possible by donor generosity, allow her to give back and make someone else’s journey a little easier, all while healing a part … Continued
Get email updates about research news, action alerts, and ways to join the fight.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
